Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human antibodies against noncircumsporozoite proteins block Plasmodium falciparum parasite development in hepatocytes
Amanda Fabra-García, … , Teun Bousema, Robert W. Sauerwein
Amanda Fabra-García, … , Teun Bousema, Robert W. Sauerwein
Published February 15, 2022
Citation Information: JCI Insight. 2022;7(6):e153524. https://doi.org/10.1172/jci.insight.153524.
View: Text | PDF
Research Article Infectious disease Vaccines

Human antibodies against noncircumsporozoite proteins block Plasmodium falciparum parasite development in hepatocytes

  • Text
  • PDF
Abstract

Sporozoite-based approaches currently represent the most effective vaccine strategies for induction of sterile protection against Plasmodium falciparum (Pf) malaria. Clinical development of subunit vaccines is almost exclusively centered on the circum-sporozoite protein (CSP), an abundantly expressed protein on the sporozoite membrane. Anti-CSP antibodies are able to block sporozoite invasion and development in human hepatocytes and subsequently prevent clinical malaria. Here, we have investigated whether sporozoite-induced human antibodies with specificities different from CSP can reduce Pf-liver stage development. IgG preparations were obtained from 12 volunteers inoculated with a protective immunization regime of whole sporozoites under chloroquine prophylaxis. These IgGs were depleted for CSP specificity by affinity chromatography. Recovered non-CSP antibodies were tested for sporozoite membrane binding and for functional inhibition of sporozoite invasion of a human hepatoma cell line and hepatocytes both in vitro and in vivo. Postimmunization IgGs depleted for CS specificity of 9 of 12 donors recognized sporozoite surface antigens. Samples from 5 of 12 donors functionally reduced parasite-liver cell invasion or development using the hepatoma cell line HC-04 and FRG-huHep mice containing human liver cells. The combined data provide clear evidence that non-CSP proteins, as yet undefined, do represent antibody targets for functional immunity against Pf parasites responsible for malaria.

Authors

Amanda Fabra-García, Annie S.P. Yang, Marije C. Behet, Zen Yap, Youri van Waardenburg, Swarnendu Kaviraj, Kjerstin Lanke, Geert-Jan van Gemert, Matthijs M. Jore, Teun Bousema, Robert W. Sauerwein

×

Figure 1

Induced sporozoite- and CSP-specific IgGs after immunization.

Options: View larger image (or click on image) Download as PowerPoint
Induced sporozoite- and CSP-specific IgGs after immunization.
Data repre...
Data represent specific IgG (μg/mL) corresponding to the lowest concentration that showed reactivity in ELISA compared with samples preimmunization (endpoint). Thresholds are set at the mean of preimmunization IgG of the 12 volunteers tested at 1 mg/mL + 3 SDs of the mean. OD450, 0.36 for the sporozoite ELISA; OD450, 0.59 for the CSP ELISA. Gray bars represent the reactivity of the IgGs against sporozoites, and black bars represent the reactivity against CSP.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts